Comparative Biological and Clinical Outcomes after a Switch from a Virologically Unsuccessful First Protease Inhibitor–Containing Antiretroviral Combination to a 3‐Drug Regimen Containing Efavirenz, Nevirapine, or Abacavir | Zendy

Sophie Abgrall | Zendy; Patrick Yéni | Zendy; Olivier Bouchaud | Zendy; Dominique Costagliola | Zendy

Open Access

Comparative Biological and Clinical Outcomes after a Switch from a Virologically Unsuccessful First Protease Inhibitor–Containing Antiretroviral Combination to a 3‐Drug Regimen Containing Efavirenz, Nevirapine, or Abacavir

Author(s) -

Sophie Abgrall,

Patrick Yéni,

Olivier Bouchaud,

Dominique Costagliola

Publication year - 2006

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/509578

Subject(s) - efavirenz , nevirapine , abacavir , lamivudine , regimen , medicine , protease inhibitor (pharmacology) , cart , zidovudine , stavudine , reverse transcriptase inhibitor , viral load , pharmacology , atazanavir , virology , hazard ratio , oncology , viral disease , human immunodeficiency virus (hiv) , antiretroviral therapy , virus , confidence interval , hepatitis b virus , mechanical engineering , engineering

Incomplete adherence is the main cause of antiretroviral therapy failure during initial combination antiretroviral therapy (cART). A switch to a protease inhibitor-sparing cART may be useful when a patient does not tolerate a first protease inhibitor-containing cART regimen.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research